Buprenorphine-Naloxone for Kratom Withdrawal
Buprenorphine-naloxone (Suboxone) is effective for treating kratom withdrawal and dependence, with dosing directly correlated to the amount of kratom used: initiate with 4-8 mg/day for patients using <20 g kratom daily, or 12-16 mg/day for those using >40 g kratom daily 1.
Evidence Base and Rationale
While the provided guidelines address traditional opioid withdrawal 2, kratom produces opioid-like dependence through its active alkaloids (mitragynine and 7-hydroxymitragynine) that act as partial mu-opioid agonists 3. Multiple case series demonstrate that buprenorphine-naloxone successfully treats kratom withdrawal with similar principles to traditional opioid use disorder 1, 4, 3, 5.
Practical Treatment Algorithm
Initial Assessment
- Confirm kratom withdrawal symptoms: myalgia, joint pain, lacrimation, rhinorrhea, yawning, insomnia, diarrhea, anxiety, restlessness, irritability, depressed mood, tremors, and chills 3
- Quantify daily kratom use (in grams) to guide initial dosing 1
- Time since last use: Induction can begin as early as 8 hours after last kratom use—significantly earlier than traditional opioids 4
Dosing Strategy
For patients using <20 g kratom/day:
- Start with 4-8 mg buprenorphine-naloxone daily 1
- Reassess after 30-60 minutes
- Titrate based on withdrawal severity
For patients using >40 g kratom/day:
- Start with 12-16 mg buprenorphine-naloxone daily 1
- May require higher maintenance doses (up to 24 mg/day) for prolonged withdrawal symptoms or co-occurring pain 4
For intermediate doses (20-40 g/day):
- Start with 8-12 mg buprenorphine-naloxone daily 1
Maintenance Considerations
- Target maintenance doses are similar to traditional opioid use disorder (typically 16 mg/day) 4
- Multiple daily dosing (divided doses) may be beneficial for prolonged withdrawal symptoms 4
- Duration: Continue maintenance therapy with addiction counseling; kratom withdrawal symptoms may persist despite treatment 4
Critical Differences from Traditional Opioid Withdrawal
Earlier Induction Window
Unlike traditional opioids where you must wait 12+ hours for short-acting opioids or 24+ hours for extended-release formulations 2, kratom allows buprenorphine induction as early as 8 hours after last use 4. This reduces the risk of precipitated withdrawal.
No COWS Score Validation
The Clinical Opioid Withdrawal Scale (COWS) used for traditional opioid withdrawal 2 has not been validated for kratom. Rely on clinical assessment of withdrawal symptoms described above 3.
Dose-Response Relationship
A strong correlation (r=0.84) exists between kratom dose and required buprenorphine-naloxone dose 1, making quantification of kratom use particularly important—unlike traditional opioid withdrawal where severity assessment drives dosing.
Important Caveats
Monitoring Requirements
- Urine drug screening for kratom alkaloids should be available, as standard opioid screens do not detect kratom 4
- Kratom may inhibit cytochrome P450 enzymes and P-glycoprotein, creating potential drug interactions 5
Polysubstance Use
Patients with concurrent substance use disorders may require:
Prolonged Withdrawal
Unlike traditional opioid withdrawal, kratom withdrawal symptoms may persist despite adequate buprenorphine-naloxone treatment 4. This requires patient counseling and expectation management.
Special Populations
In pregnancy, buprenorphine-naloxone has been used successfully for kratom use disorder 6, though experience is limited. Neonatal withdrawal symptoms have been reported with maternal kratom use 3.
Alternative Treatment Option
Methadone is emerging as an alternative when buprenorphine is unsuitable, with mean doses of 98.6 mg (range 35-190 mg) showing 93% treatment retention 7. However, buprenorphine-naloxone remains the first-line treatment given broader clinical experience and easier access 1, 4, 3, 5.